| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Should you keep an eye on Cns Pharmaceuticals (NASDAQ:CNSP) management before September?
 | By Rifka Kats | Macroaxis Story |
Lets try to recap the odds of Cns Pharmaceuticals to fully recover from the recent decline as its shares went up 24.86%. Cns Pharmaceuticals's current daily volatility is 5.47 percent, with a beta of 0.06 and an alpha of -0.58 over DOW. While many traders are getting carried away by overanalyzing favorable retirement market, it is reasonable to recap Cns Pharmaceuticals. We will evaluate if Cns Pharmaceuticals shares are reasonably priced going into September.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Raphi Shpitalnik
Cns Pharmaceuticals currently holds roughly 2.63 M in cash with (7.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.16. One of the ways to look at asset utilization of Cns Pharmaceuticals is to check how much profit was generated for every dollar of assets it reports. Cns Pharmaceuticals shows a negative utilization of assets of -170.24 percent, losing $1.7 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Cns Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Cns Pharmaceuticals. Your research has to be compared to or analyzed against Cns Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Cns Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Cns Pharmaceuticals.
Investing in Cns Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Cns Pharmaceuticals along with other instruments in the same portfolio. Using conventional technical analysis and fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cns Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Watch out for price decline
Please consider monitoring Cns Pharmaceuticals on a daily basis if you are holding a position in it. Cns Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Cns Pharmaceuticals stock to be traded above the $1 level to remain listed. If Cns Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Cns Pharmaceuticals's Liquidity
Cns Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Cns Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cns Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Cns Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Cns Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Cns Pharmaceuticals's total debt and its cash.
Cns Pharmaceuticals Gross Profit
Cns Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Cns Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Cns Pharmaceuticals Gross Profit growth over the last 10 years. Please check Cns Pharmaceuticals' gross profit and other fundamental indicators for more details.
Cns Pharmaceuticals Correlation with Peers
Investors in Cns can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Cns Pharmaceuticals. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Cns Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Cns is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with your current brokerage. Please check volatility of Cns for more details
Another Deeper Perspective
Cns Pharmaceuticals secures Sharpe Ratio (or Efficiency) of -0.043, which signifies that the company had -0.043% of return per unit of risk over the last month. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Cns Pharmaceuticals exposes twenty-seven different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to confirm Cns Pharmaceuticals risk adjusted performance of (0.17), and Mean Deviation of 3.14 to double-check the risk estimate we provide.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Cns Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.